marked.bio

Company

Henan Genuine Biotech

2 active trials that select patients by a biomarker on marked.bio.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

2 of 2 trials shown

  1. A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib

    Recruiting Phase 1/2 Henan Genuine Biotech Started 2025Primary completion 2027-07 NCT07362940

    GEN-725 tablets + Dositinib mesylate tablets

    Patients with a positive EGFR mutation. (For patients with prior third-generation EGFR-TKI therapy, post-progression EGFR mutati…

    EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer

  2. A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation

    Recruiting Phase 1/2 Henan Genuine Biotech Started 2022Primary completion 2027-12 NCT07231068

    Dositinib mesylate tablets

    Patients with confirmed EGFR activating mutations that are sensitive to EGFR TKI at any time after initial diagnosis, in dose escalation p…

    EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer